Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.11.20.20234013: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The trial was approved by the institutional review boards of participating institutions and the state of Buenos Aires, and registered in the Dirección de Sangre y Medicina Transfusional del MSAL (PAEPCC19; May 29
Consent: Those with detectable SARS-CoV2 RNA were transported to study hospitals and invited to sign the informed consent.Randomization Trial design and oversight: We conducted a randomized, double-blind, placebo-controlled trial between June 4 2020 and October 25 2020 (date of last patient completing follow up) at Hospitals Dr. Blinding not detected. Power Analysis A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power … SciScore for 10.1101/2020.11.20.20234013: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The trial was approved by the institutional review boards of participating institutions and the state of Buenos Aires, and registered in the Dirección de Sangre y Medicina Transfusional del MSAL (PAEPCC19; May 29
Consent: Those with detectable SARS-CoV2 RNA were transported to study hospitals and invited to sign the informed consent.Randomization Trial design and oversight: We conducted a randomized, double-blind, placebo-controlled trial between June 4 2020 and October 25 2020 (date of last patient completing follow up) at Hospitals Dr. Blinding not detected. Power Analysis A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04479163 Completed Prevention of Severe Covid-19 in Infected Elderly by Early A… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
SciScore for 10.1101/2020.11.20.20234013: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement The trial was approved by the institutional review boards of participating institutions and the state of Buenos Aires, and registered in the Dirección de Sangre y Medicina Transfusional del MSAL (PAEPCC19; May 29 2020), Plataforma PRIISA (1421; May 17 2020), and clinicaltrials.gov (NCT04479163; July 23 2020). Randomization After obtaining written informed consent, eligible patients were randomized to receive 250 ml of convalescent plasma with an IgG titer against SARS-CoV2 spike (S) protein >1:1,000 (COVIDAR IgG, Instituto Leloir, Argentina) or placebo (normal saline 0.9%) administered over 1.5 to 2 hours in a 1:1 ratio. Blinding not detected. Power Analysis A total … SciScore for 10.1101/2020.11.20.20234013: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement The trial was approved by the institutional review boards of participating institutions and the state of Buenos Aires, and registered in the Dirección de Sangre y Medicina Transfusional del MSAL (PAEPCC19; May 29 2020), Plataforma PRIISA (1421; May 17 2020), and clinicaltrials.gov (NCT04479163; July 23 2020). Randomization After obtaining written informed consent, eligible patients were randomized to receive 250 ml of convalescent plasma with an IgG titer against SARS-CoV2 spike (S) protein >1:1,000 (COVIDAR IgG, Instituto Leloir, Argentina) or placebo (normal saline 0.9%) administered over 1.5 to 2 hours in a 1:1 ratio. Blinding not detected. Power Analysis A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction. Sex as a biological variable The mean age of subjects was 77.1 (S.D. 8.6) years; 100 (62.5%) were females (Table 1). Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04479163 Completed Prevention of Severe Covid-19 in Infected Elderly by Early A... Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
-
